.png){kind=logo}
Utrecht, 20.12.2024 - Validaide, a leading digital platform for pharma lane risk management and industry collaboration, is thrilled to announce a strategic partnership with SkyCell, a global leader in safe, secure, and sustainable pharma supply chain solutions. This partnership includes an investment from SkyCell, making it a key shareholder and reaffirming Validaide’s position as a leader in the digitization of pharmaceutical logistics.
SkyCell’s investment enables Validaide to further scale its platform and introduce innovative features while remaining an independent, trusted resource for over 1,600 companies worldwide. This collaboration underscores a shared vision to deliver enhanced solutions for lane risk assessment and supply chain optimization to benefit the growing user base.
Strengthening Validaide’s Neutral and Collaborative Platform
Validaide remains operating as a neutral and independent company, fostering collaboration among key stakeholders, including pharmaceutical companies, airlines, freight forwarders, and packaging providers. Neutrality is a foundational pillar of Validaide’s operations, enabling users to rely on scientifically validated risk assessments and robust collaboration tools.
“Our commitment to neutrality has been a cornerstone of the company’s growth and remains a guiding principle for the future.” said Eelco de Jong, co-founder and managing director of Validaide.
"This partnership enhances Validaide’s capabilities while safeguarding its neutrality, ensuring it remains the go-to solution for safer, more efficient supply chains.", added Richard Ettl, CEO of SkyCell.
Driving Lane Risk Assessment Excellence
Validaide has established itself as a leader in lane risk assessment, offering innovative tools like the Pharma Index - a benchmark metric that evaluates the quality of healthcare shipments using key performance indicators. This transparency empowers users to mitigate risks and make informed decisions across their supply chains.
“Validaide’s platform fosters collaboration and delivers unmatched insights into pharma logistics risks,” said Nico Ros, CTO of SkyCell. “Together, we aim to broaden its impact and bring these benefits to even more companies globally.”
Accelerating Innovation and Delivering New Capabilities
SkyCell’s investment unlocks resources for Validaide to enhance its technology platform and roll out new features designed to:
· Expedite lane approvals, reducing supply chain delays.
· Enhance risk modeling tools for greater accuracy.
· Streamline regulatory compliance, ensuring smoother operations.
· Incorporate emissions reporting, supporting sustainability goals.
These advancements will strengthen Validaide’s position as the go-to platform for pharma lane risk assessment and collaboration, helping users navigate the complexities of modern supply chains with greater efficiency.
“SkyCell has always been an innovation leader in pharma logistics, from the use of IoT devices to the development of sustainability assessments.” said Mark Bijl, co-founder and CTO of Validaide. “We are excited to leverage this expertise to further develop our platform and better serve our customers.”
A Shared Vision for Pharma Supply Chains
Validaide and SkyCell share a commitment to creating safer, more efficient, and sustainable supply chains. Validaide’s transparency and adherence to scientific standards in calculating the Pharma Index make it the trusted choice for pharmaceutical companies, freight forwarders, airlines, and packaging providers.
“Our longstanding relationship with SkyCell has been built on shared goals,” said Eelco de Jong. “This next step in our journey together enables us to combine Validaide’s qualitative operational data with SkyMind’s quantitative data, offering a comprehensive solution for the pharma industry while maintaining our neutrality. Together, we look forward to helping our customers make better, more informed supply chain decisions.”
About Validaide
Validaide is a leading software provider specializing in lane risk assessment for the freight forwarding and pharmaceutical industries. Based in the Netherlands, Validaide’s platform fosters collaboration and transparency among industry stakeholders to create safer, more efficient supply chains.
Further details about Validaide’s commitment to neutrality can be found here: https://www.validaide.com/neutrality-commitment
About SkyCell
SkyCell is a purpose-led technology company transforming the pharmaceutical supply chain through a combination of proprietary software, hardware, and big data. It is the leading manufacturer of hybrid temperature-controlled door-to-door container solutions. These allow pharma companies to optimize their supply chain by reducing, and even predicting, the risks associated with delivering sensitive drugs by air.
Its SaaS solution, SkyMind, combines simulation data with operational data (S+O data), enabling pharma companies to have real-time, end-to-end oversight of every shipment around the world. Its automated approval capability reduces quality approval time from an average of days to just hours, getting life-changing drugs to consumers faster.
Designed with sustainability as a core principle, SkyCell is climate-neutral in its own direct operations (Scopes 1&2 reduced and removed) today and has committed to the goal of end-to-end net-zero emissions by 2040.
Comments